Abstract
Background: Cisplatin (CDDP) is one of the most active chemotherapeutic agents but is among the most emetogenic drugs. The emetic side-effects of CDDP-containing intraarterial chemotherapy have not been evaluated in a prospective randomized trial and the efficacy of serotonin antagonists in preventing the emesis associated with this method of CDDP administration has not been assessed. Methods: CDDP 50 mg/m2 and methotrexate 30 mg/m2 were administered every 3 weeks through intraarterial catheters placed in the bilateral internal iliac arteries. Patients were classified into two groups: granisetron treatment group (group G) and no treatment group (group NG) with the first course of chemotherapy, crossing over with the second course. The patients in group G received granisetron 40 μg/kg by intravenous infusion. Results: Although intraarterial CDDP administration produced less emesis than intravenous CDDP administration, at the same concentration, gastrointestinal toxicity is still the most unpleasant side-effect for patients. Granisetron administration significantly reduced nausea and vomiting during the acute emetic phase (an evaluation of treatment as very effective and effective was made in 89% in group G and 33% in group NG (P <0.001). Complete control of emesis was achieved in 68 and 18% of patients in groups G and NG, respectively (P <0.0001). Conclusion: A single prophylactic infusion of granisetron was effective in preventing the nausea and vomiting associated with intraarterial CDDP-containing therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 87-91 |
| Number of pages | 5 |
| Journal | Japanese Journal of Clinical Oncology |
| Volume | 29 |
| Issue number | 2 |
| Publication status | Published - Feb 1999 |
| Externally published | Yes |
Fingerprint
Keywords
- Anti-emetic efficacy
- Bladder cancer
- Cisplatin
- Crossover trial
- Granisetron
- Intra-arterial chemotherapy
ASJC Scopus subject areas
- Oncology
Cite this
Antiemetic efficacy of granisetron : A randomized crossover study in patients receiving cisplatin-containing intraarterial chemotherapy. / Uchida, Katsunori; Akaza, Hideyuki; Hattori, Kazunori; Noguchi, Ryosuke; Kondo, Fukuji; Ishikawa, Satoru; Ohtani, Mikinobu; Hinotsu, Shiro; Koiso, Kenkichi.
In: Japanese Journal of Clinical Oncology, Vol. 29, No. 2, 02.1999, p. 87-91.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Antiemetic efficacy of granisetron
T2 - A randomized crossover study in patients receiving cisplatin-containing intraarterial chemotherapy
AU - Uchida, Katsunori
AU - Akaza, Hideyuki
AU - Hattori, Kazunori
AU - Noguchi, Ryosuke
AU - Kondo, Fukuji
AU - Ishikawa, Satoru
AU - Ohtani, Mikinobu
AU - Hinotsu, Shiro
AU - Koiso, Kenkichi
PY - 1999/2
Y1 - 1999/2
N2 - Background: Cisplatin (CDDP) is one of the most active chemotherapeutic agents but is among the most emetogenic drugs. The emetic side-effects of CDDP-containing intraarterial chemotherapy have not been evaluated in a prospective randomized trial and the efficacy of serotonin antagonists in preventing the emesis associated with this method of CDDP administration has not been assessed. Methods: CDDP 50 mg/m2 and methotrexate 30 mg/m2 were administered every 3 weeks through intraarterial catheters placed in the bilateral internal iliac arteries. Patients were classified into two groups: granisetron treatment group (group G) and no treatment group (group NG) with the first course of chemotherapy, crossing over with the second course. The patients in group G received granisetron 40 μg/kg by intravenous infusion. Results: Although intraarterial CDDP administration produced less emesis than intravenous CDDP administration, at the same concentration, gastrointestinal toxicity is still the most unpleasant side-effect for patients. Granisetron administration significantly reduced nausea and vomiting during the acute emetic phase (an evaluation of treatment as very effective and effective was made in 89% in group G and 33% in group NG (P <0.001). Complete control of emesis was achieved in 68 and 18% of patients in groups G and NG, respectively (P <0.0001). Conclusion: A single prophylactic infusion of granisetron was effective in preventing the nausea and vomiting associated with intraarterial CDDP-containing therapy.
AB - Background: Cisplatin (CDDP) is one of the most active chemotherapeutic agents but is among the most emetogenic drugs. The emetic side-effects of CDDP-containing intraarterial chemotherapy have not been evaluated in a prospective randomized trial and the efficacy of serotonin antagonists in preventing the emesis associated with this method of CDDP administration has not been assessed. Methods: CDDP 50 mg/m2 and methotrexate 30 mg/m2 were administered every 3 weeks through intraarterial catheters placed in the bilateral internal iliac arteries. Patients were classified into two groups: granisetron treatment group (group G) and no treatment group (group NG) with the first course of chemotherapy, crossing over with the second course. The patients in group G received granisetron 40 μg/kg by intravenous infusion. Results: Although intraarterial CDDP administration produced less emesis than intravenous CDDP administration, at the same concentration, gastrointestinal toxicity is still the most unpleasant side-effect for patients. Granisetron administration significantly reduced nausea and vomiting during the acute emetic phase (an evaluation of treatment as very effective and effective was made in 89% in group G and 33% in group NG (P <0.001). Complete control of emesis was achieved in 68 and 18% of patients in groups G and NG, respectively (P <0.0001). Conclusion: A single prophylactic infusion of granisetron was effective in preventing the nausea and vomiting associated with intraarterial CDDP-containing therapy.
KW - Anti-emetic efficacy
KW - Bladder cancer
KW - Cisplatin
KW - Crossover trial
KW - Granisetron
KW - Intra-arterial chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=0033070626&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033070626&partnerID=8YFLogxK
M3 - Article
VL - 29
SP - 87
EP - 91
JO - Japanese Journal of Clinical Oncology
JF - Japanese Journal of Clinical Oncology
SN - 0368-2811
IS - 2
ER -